{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:33:56Z","timestamp":1756463636804},"reference-count":21,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2019,4,30]]},"DOI":"10.5582\/ddt.2019.01020","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T18:02:47Z","timestamp":1557511367000},"page":"122-127","source":"Crossref","is-referenced-by-count":5,"title":["Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach"],"prefix":"10.5582","volume":"13","author":[{"given":"Carmen","family":"Rodr\u00edguez-Cerdeira","sequence":"first","affiliation":[{"name":"Efficiency, Quality and Costs in Health Services Research Group (EFISALUD), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO"},{"name":"Department of Dermatology. CHUVI. Hospital do Meixoeiro and University of Vigo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Mu\u00f1oz-Garz\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy. CHUVI. Hospital do Meixoeiro"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Gonz\u00e1lez-Cesp\u00f3n","sequence":"additional","affiliation":[{"name":"Efficiency, Quality and Costs in Health Services Research Group (EFISALUD), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Alter M, Hillen U, Leiter U, Sachse M, Gutzmer R. Current diagnosis and treatment of basal cell carcinoma. J Dtsch Dermatol Ges. 2015; 13:863-874.","DOI":"10.1111\/ddg.12798"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Goldenberg G, Karagiannis T, Palmer JB, Lotya J, O&apos;Neill C, Kisa R, Herrera V, Siegel DM. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study. J Am Acad Dermatol. 2016; 75:957-966.","DOI":"10.1016\/j.jaad.2016.06.020"},{"key":"3","unstructured":"3. Berking C, Hauschild A, K\u00f6lbl O, Mast G, Gutzmer R. Basal cell carcinoma treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014; 111:389-295."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, Harwood CA. Challenges and new horizons in the management of advanced basal cell carcinoma: A UK perspective. Br J Cancer. 2014; 111:1476-1481.","DOI":"10.1038\/bjc.2014.270"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004; 23:389-402.","DOI":"10.1023\/B:CANC.0000031775.04618.30"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: A new treatment for basal cell carcinoma. Clin Ther. 2012; 34:2039-2050.","DOI":"10.1016\/j.clinthera.2012.08.011"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vornicova O, Bar-Sela G. Rapid response to vismodegib in a patient with advanced basal cell carcinoma. JAAD Case Rep. 2015; 1:267-268.","DOI":"10.1016\/j.jdcr.2015.06.010"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Girardi D, Barrichello A, Fernandes G, Pereira A. Targeting the Hedgehog pathway in cancer: Current evidence and future perspectives. Cells. 2019; 8:E153.","DOI":"10.3390\/cells8020153"},{"key":"9","unstructured":"9. Lyons TG, O&apos;Kane GM, Kelly CM. Efficacy and safety of vismodegib: A new therapeutic agent in the treatment of basal cell carcinoma. Expert Opin Drug Saf. 2014; 138:1125-1132."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Yan BY, Hibler BP, Menge T, Dunn L, Ho AL, Rossi AM. Sonic Hedgehog pathway inhibitors: From clinical trials to clinical practice. Br J Dermatol. 2019. doi: 10.1111\/bjd.17692.","DOI":"10.1111\/bjd.17692"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dreier J, Cheng PF, Bogdan Alleman I, Hafner J, Tschopp A, Goldinger SM, Levesque MP, Dummer R. Basal cell carcinomas in a tertiary referral centre: A systematic analysis. Br J Dermatol. 2014; 71:1066-1072.","DOI":"10.1111\/bjd.13217"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Meiss F, Andrlov\u00e1 H, Zeiser R. Vismodegib. Recent Results Cancer Res. 2018; 211:125-139.","DOI":"10.1007\/978-3-319-91442-8_9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sekulic A, Migden MR, Oro A E, <i>et al<\/i>. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366:2171-2179.","DOI":"10.1056\/NEJMoa1113713"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sekulic A, Migden MR, Lewis K, <i>et al<\/i>. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015; 72:1021-1026.","DOI":"10.1016\/j.jaad.2015.03.021"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sekulic A, Migden MR, Basset-Seguin N, <i>et al<\/i>. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017; 17:332.","DOI":"10.1186\/s12885-017-3286-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Basset-Seguin N, Hauschild A, Grob JJ, <i>et a<\/i>l. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16:729-736.","DOI":"10.1016\/S1470-2045(15)70198-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dr\u00e9no B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, Grob JJ, Puig S, Gilberg F, Bergstr\u00f6m D, Page DR, Rogers G, Schadendorf D. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): A randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017; 18:404-412.","DOI":"10.1016\/S1470-2045(17)30072-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mortier L, Bertrand N, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, Bernard Guillot, Templier C, Desmedt E, Duhamel A, Guerreschi P. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). J Clin Oncol. 2018; 36 (15 Suppl): 9509-9509.","DOI":"10.1200\/JCO.2018.36.15_suppl.9509"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014; 70:60-69.","DOI":"10.1016\/j.jaad.2013.09.012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pollom EL, Bui TT, Chang ALS, Colevas AD, Hara WY. Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma. JAMA Dermatol. 2015; 151:998-1001.","DOI":"10.1001\/jamadermatol.2015.0326"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rizzo JM, Segal RJ, Zeitouni NC. Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis Photodyn Ther. 2018; 21:58-62.","DOI":"10.1016\/j.pdpdt.2017.10.028"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/13\/2\/13_2019.01020\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T23:29:34Z","timestamp":1557530974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/13\/2\/13_2019.01020\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2019.01020","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]}}}